The Long Run with Luke Timmerman
by Timmerman Report
"The Long Run"Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous. Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Episodes
-
Ep213: Daphne Koller on The Moment in AI Drug Discovery
Daphne Koller, founder and CEO of South San Francisco-based Insitro, on the moment in AI drug discovery.
-
Ep212: Tim Shannon on Creating Targeted Protein Degraders as Medicines
Tim Shannon is a general partner at Canaan Partners, and a founding executive at a pair of targeted protein degrader companies -- Arvinas and Halda Therapeutics.
-
Ep211: Ardem Patapoutian on Touch, Pain & New Discoveries in Neuroscience
Arden Patapoutian, professor of neuroscience at Scripps Research and Howard Hughes Medical Institute, on new discoveries in neuroscience related to our sense of touch, pain, and more.
-
Ep210: Cameron Turtle on Long-Lasting Antibodies for Immune Disorders
Cameron Turtle, CEO of Waltham, Mass.-based Spyre Therapeutics, on developing long-lasting antibodies for immune disorders.
-
Ep209: Mathai Mammen on Developing Drugs Against Undruggable Targets
Mathai Mammen, CEO of Cambridge, Mass.-based Parabilis Medicine, on developing alpha helical peptide molecules against hard targets of disease.
-
Ep208: Gary Nabel on Developing a Vaccine for Epstein-Barr Virus
Gary Nabel, CEO of Weston, Mass.-based ModeX Therapeutics, on developing a vaccine for Epstein-Barr Virus.
-
Ep207: Jason Coloma on Genetic Medicines for Kidney Diseases
Jason Coloma, CEO of South San Francisco-based Maze Therapeutics, on developing small molecule drugs based on human genetics for kidney diseases.
-
Ep206: Lyn Baranowski on Inhalable Medicines for Severe Lung Diseases
Lyn Baranowski, CEO of Boston-based Avalyn Pharma, on developing inhalable medicines for severe lung diseases.
-
Ep205: Heather Turner on a Schizophrenia Drug Patients Can Stick With
Heather Turner, CEO of New York-based LB Pharma, on developing a new schizophrenia drug designed to better cross the blood-brain barrier, be dosed once daily, and make it easier for patients to take long term.
-
Ep204: Troy Wilson on Precision Cancer Drugs and Combos
Troy Wilson, CEO of San Diego-based Kura Oncology, on his career in biotech and developing targeted cancer drugs.
-
Ep203: Sri Kosuri on Small Molecule Correctors of Disease
Sri Kosuri, co-founder and CEO of Emeryville, Calif.-based Octant Bio, on small molecules designed to correct protein misfolding and mistrafficking at the root of many diseases.
-
Ep202: Becky Pferdehirt on Reimagining Science for the AI Era
Becky Pferdehirt, CEO of Emeryville, CA-based Radial, the life sciences unit of Astera Institute, on reimagining biology to take advantage of advances in AI.
-
Ep201: Jeremy Levin on Biotech in the Balance
Jeremy Levin, executive chair of Ovid Therapeutics, discusses his new book "Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust."
-
Ep200: Richard Pops Reflects on a 35-Year Career in Biotech
Alkermes CEO Richard Pops reflects on his 35-year career leading the company and its new opportunity in orexin biology for sleep disorders and more neurological conditions.
-
Ep199: Martin Burke on Making Small Molecule Medicines for the AI Era
Marty Burke, a professor of chemistry at the University of Illinois and co-founder of Excelsior Sciences, on making small molecule synthesis more automated for AI.
-
Ep198: Abbas Kazimi on Computation and Culture for Drug Discovery
Abbas Kazimi, CEO of Boston-based Nimbus Therapeutics, on computation and culture for drug discovery.
-
Ep197: Viswa Colluru on Discovering Drugs Inspired by Mother Nature
Viswa Colluru, founder and CEO of Boulder, Colo.-based Enveda, on drug discovery with a chemistry platform inspired by natural products.
-
Ep196: Otello Stampacchia on Europe's Biotech Crisis
Otello Stampacchia, founder and managing director of Omega Funds, on attempting to reform Europe's biotech investment climate.
-
Ep195: Ken Song on T-cell Engagers for Autoimmune Diseases
Ken Song, CEO of San Diego-based Candid Therapeutics, on developing bispecific T-cell engaging antibodies for autoimmune disease.
-
Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery
Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery by Timmerman Report
-
Ep193: Ron Renaud on Helping People Lose Weight With GLP-1 Medicines
Ron Renaud, CEO of Waltham, Mass.-based Kailera Therapeutics, on developing GLP-1 based medicines to help people lose weight and live healthier lives.
-
Ep192: Kate Haviland on Following the Science to Precision Immunology
Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.
-
Ep191: Emily Conley on Small Molecules to Correct a Rare Kidney Disease
Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD).
-
Ep190: Neil Kumar on Building a Rare Disease Drug Company
Neil Kumar is founder and CEO of Palo Alto, Calif.-based BridgeBio Pharma, a rare disease drug developer.
-
Ep189: Marc Tessier-Lavigne on Reinventing Drug Discovery with AI
Marc Tessier-Lavigne, CEO of South San Francisco-based Xaira Therapeutics, on reinventing drug discovery with AI.
-
Ep188: Art Krieg on Innate Immune System Activators for Cancer
Art Krieg, founder and CEO of Zola Therapeutics, on developing innate immune system activators for cancer.
-
Ep187: Eric Fischer on Creating a New Class of Medicines
Eric Fischer, a professor at Dana-Farber Cancer Institute, on creating a new class medicines -- targeted protein degraders.
-
Ep186: Bruce Levine & Mags McCarthy on a Song About Science and Hope
Bruce Levine, a CAR-T cell therapy researcher at the University of Pennsylvania, and Mags McCarthy, a country music star, discuss their new song about science and hope for cancer patients.
-
Ep185: Dr. Lachelle Weeks on Predicting Leukemia Risk At Scale
Dr. Lachelle Weeks is a physician-scientist at Dana-Farber Cancer Institute working on a project to predict leukemia risk based on widely available blood samples.
-
Ep184: Jen Adair on Affordable, Accessible Gene & Cell Therapies
Jen Adair, professor and associate director of the Horae Gene Therapy Center at the University of Massachusetts Chan Medical School, on creating more affordable and accessible cell and gene therapies.
-
Ep183: Sabah Oney on CAR-T Cells Against Solid Tumors
Sabah Oney, CEO of Philadelphia and San Francisco-based Dispatch Biotherapeutics, on engineering CAR-T cells that can kill solid tumors.
-
Ep182: Andy Rachleff & Yung Lie on Creative Ways to Back Science
Andy Rachleff and Yung Lie, board chair and CEO of Damon Runyon Cancer Research Foundation, on creative ways to support science amid budget cuts.
-
Ep181: Claire Mazumdar on a Two-Pronged Attack Against Cancer
Claire Mazumdar, CEO of Boston-based Bicara Therapeutics, on developing a bifunctional antibody for head and neck cancer.
-
Ep180: John Rinn on Discovering Drugs Based on Long Non-Coding RNA
John Rinn, professor at the University of Colorado and co-founder of Lincswitch Therapeutics, on exploring long non-coding RNA.
-
Ep179: Ethan Weiss & Josh Lehrer on a New Idea for Cardiovascular Disease & Diabetes
Marea Therapeutics CEO Josh Lehrer and CSO Ethan Weiss on a new angle of attack against cardiovascular disease and diabetes.
-
Ep178: Peyton Greenside on ML-Guided Biologics Discovery
Peyton Greenside, co-founder and CEO of BigHat Biosciences, on machine-learning guided biologic drug discovery.
-
Ep177: Kevin Parker on Finding Cancer Drug Targets
Kevin Parker, CEO of Cartography Biosciences, on finding new cancer drug targets.
-
Ep176: David Roblin on Building a TechBio Company
David Roblin, CEO of London-based Relation Therapeutics, on building a techbio discovery company.
-
Ep175: Andy Scharenberg on in vivo CAR-T cell therapies
Andy Scharenberg, CEO of Seattle-based Umoja Biopharma, on developing in vivo CAR-T cell therapies.
-
Ep174: Najat Khan on the TechBio Movement
Najat Khan, chief R&D and chief commercial officer of Recursion, on using technology to improve drug discovery.
-
Ep173: Robert Blum on Building a Fully Integrated Biopharma For Muscle Disorders
Robert Blum, CEO of South San Francisco-based Cytokinetics, on building a fully integrated biopharma to treat muscle disorders.
-
Ep172: Mostafa Ronaghi on Studying Live Cells at Scale
Mostafa Ronaghi, co-founder and executive board member of Cellanome, on developing technology to look at live cells and cellular interactions at scale.
-
Ep171: Ram Aiyar on RNA Editing Medicines
Ram Aiyar, CEO of Cambridge, Mass.-based Korro Bio, on RNA editing medicines.
-
Ep170: David Schenkein on Investing in the Future of Biotech
David Schenkein, general partner at GV, on investing in the future of biotech.
-
Ep169: Kevin Fitzgerald on the Past & Future of RNAi Medicines
Alnylam Pharmaceuticals chief scientific officer Kevin Fitzgerald on the past, present & future of RNA interference medicines.
-
Ep168: Jonathan Bricker on How to Quit Smoking & Prevent Cancer
Jonathan Bricker, professor in the cancer prevention program at Fred Hutchinson Cancer Center, on how to quit smoking with help from tech and biotech tools.
-
Ep167: Leslie Williams on transfer RNA therapies
Leslie Williams, CEO of Boston-based hC Bioscience, on developing transfer RNA therapies.
-
Ep166: Chris Garcia on Engineering Protein Drugs for Cancer, Autoimmunity
Chris Garcia, professor at Stanford University and co-founder of several biotech startups, on using protein engineering to advance new treatments for cancer and autoimmune diseases.
-
Ep165: Zach Hornby on Tackling Cancer Drug Resistance
Zach Hornby, CEO of San Diego-based Boundless Bio, on tackling cancer drug resistance.
-
Ep164: Ted Love and Alan Anderson on Raising the Bar for Sickle Cell Disease Patients
Ted Love, chairman of BIO, and Dr. Alan Anderson, executive director of Sickle Forward, on how to improve quality of life for sickle cell disease patients around the world.
About this show
"The Long Run"Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous. Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Hosted by
Timmerman Report
Categories